
上海交通大学学报(医学版) ›› 2023, Vol. 43 ›› Issue (3): 365-373.doi: 10.3969/j.issn.1674-8115.2023.03.013
收稿日期:2022-07-12
接受日期:2022-12-16
出版日期:2023-03-28
发布日期:2023-03-28
通讯作者:
夏 强,电子信箱:xiaqiang@shsmu.edu.cn。作者简介:陈 晨(1996—),女,住院医师,博士;电子信箱:18217597089@163.com。
基金资助:
CHEN Chen1(
), CHENG Zhuoan1, WANG Cun1,2, XIA Qiang1,2,3(
)
Received:2022-07-12
Accepted:2022-12-16
Online:2023-03-28
Published:2023-03-28
Contact:
XIA Qiang, E-mail: xiaqiang@shsmu.edu.cn.Supported by:摘要:
铁死亡是由于脂质活性氧自由基累积造成的细胞死亡,以铁依赖的脂质双分子层氧化性损伤为特征。铁积累和脂质过氧化是铁死亡过程中的关键标志。铁稳态、氧化还原稳态、脂质合成等过程失调可影响铁死亡。目前已报道铁死亡的主要调控轴包括胱氨酸/谷氨酸转运体(System Xc-)-谷胱甘肽(glutathione,GSH)-谷胱甘肽过氧化物酶4(glutathione peroxidase 4,GPX4)轴、辅酶Q10(coenzyme Q10,CoQ10)-铁死亡抑制蛋白(ferroptosis suppressor protein 1,FSP1)-泛醇轴、GTP环化水解酶1(GTP cyclohydrolase 1,GCH1)-四氢生物蝶呤(tetrahydrobiopterin,BH4)-二氢叶酸还原酶(dihydrofolate reductase,DHFR)-磷脂轴、二氢乳清酸脱氢酶(dehydrogenase,DHODH)-泛醇轴等。铁死亡被视为重要的细胞死亡形式,在肝细胞癌、肝缺血再灌注损伤、脂肪性肝炎、肝纤维化、肝硬化和肝脏代谢病等多种疾病中发挥重要的作用,清晰阐释铁死亡的分子机制可为上述肝脏疾病的治疗提供潜在靶点。因此,该综述主要概括和探讨铁死亡的分子特征、相关生物学过程、调控途径,以及调控铁死亡在肝脏疾病治疗中的研究现状。
中图分类号:
陈晨, 程卓安, 王存, 夏强. 铁死亡调控在肝脏疾病治疗中的研究进展[J]. 上海交通大学学报(医学版), 2023, 43(3): 365-373.
CHEN Chen, CHENG Zhuoan, WANG Cun, XIA Qiang. Research progress in ferroptosis regulation in the treatment of liver diseases[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(3): 365-373.
| Inducer | Target | Inhibitor | Target |
|---|---|---|---|
| RSL3, ML162, ML210, FIN56, FINO2 | GPX4 | Iron chelator | Iron toxicity |
| Erastin, erastin analogs, IKE, Sorafenib, Sulfasalazine, PE, glutamate, IFN-γ | System Xc- | Ferrostatin-1, liprostatin-1, deuterated PUFAs, MUFAs | Lipid peroxidation |
| FIN56 | CoQ10 | Vitamin E, α-tocopherol, RTA | Lipid propagation |
| BSO | Glutamate-cysteine ligase | Thiazolidinediones | ACSL4 |
| Statins | HMG-CoA | Baicalein, Zileuton | Lipoxygenases |
| Brequinar | DHODH | ||
| iFSP1 | FSP1 | ||
| Artemisinins | Ferritinophagy | ||
| Methotrexate | Dihydrofolate reductase |
表1 常见的铁死亡诱导剂和抑制剂
Tab 1 Common inducers and inhibitors of ferroptosis
| Inducer | Target | Inhibitor | Target |
|---|---|---|---|
| RSL3, ML162, ML210, FIN56, FINO2 | GPX4 | Iron chelator | Iron toxicity |
| Erastin, erastin analogs, IKE, Sorafenib, Sulfasalazine, PE, glutamate, IFN-γ | System Xc- | Ferrostatin-1, liprostatin-1, deuterated PUFAs, MUFAs | Lipid peroxidation |
| FIN56 | CoQ10 | Vitamin E, α-tocopherol, RTA | Lipid propagation |
| BSO | Glutamate-cysteine ligase | Thiazolidinediones | ACSL4 |
| Statins | HMG-CoA | Baicalein, Zileuton | Lipoxygenases |
| Brequinar | DHODH | ||
| iFSP1 | FSP1 | ||
| Artemisinins | Ferritinophagy | ||
| Methotrexate | Dihydrofolate reductase |
| 1 | DOLMA S, LESSNICK S L, HAHN W C, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells[J]. Cancer Cell, 2003, 3(3): 285-296. |
| 2 | YANG W S, STOCKWELL B R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells[J]. Chem Biol, 2008, 15(3): 234-245. |
| 3 | DIXON S J, LEMBERG K M, LAMPRECHT M R, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072. |
| 4 | XIE Y, HOU W, SONG X, et al. Ferroptosis: process and function[J]. Cell Death Differ, 2016, 23(3): 369-379. |
| 5 | HENTZE M W, MUCKENTHALER M U, GALY B, et al. Two to tango: regulation of mammalian iron metabolism[J]. Cell, 2010, 142(1): 24-38. |
| 6 | NEMETH E, TUTTLE M S, POWELSON J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization[J]. Science, 2004, 306(5704): 2090-2093. |
| 7 | ALVAREZ S W, SVIDERSKIY V O, TERZI E M, et al. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis[J]. Nature, 2017, 551(7682): 639-643. |
| 8 | TERZI E M, SVIDERSKIY V O, ALVAREZ S W, et al. Iron-sulfur cluster deficiency can be sensed by IRP2 and regulates iron homeostasis and sensitivity to ferroptosis independent of IRP1 and FBXL5[J]. Sci Adv, 2021, 7(22): eabg4302. |
| 9 | DU J, WANG T, LI Y, et al. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin[J]. Free Radic Biol Med, 2019, 131: 356-369. |
| 10 | MA S, HENSON E S, CHEN Y, et al. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells[J]. Cell Death Dis, 2016, 7(7): e2307. |
| 11 | BROWN C W, AMANTE J J, CHHOY P, et al. Prominin2 drives ferroptosis resistance by stimulating iron export[J]. Dev Cell, 2019, 51(5): 575-586.e4. |
| 12 | YANG W H, HUANG Z Q, WU J L, et al. A TAZ-ANGPTL4-NOX2 axis regulates ferroptotic cell death and chemoresistance in epithelial ovarian cancer[J]. Mol Cancer Res, 2020, 18(1): 79-90. |
| 13 | CHEN X, XU S, ZHAO C, et al. Role of TLR4/NADPH oxidase 4 pathway in promoting cell death through autophagy and ferroptosis during heart failure[J]. Biochem Biophys Res Commun, 2019, 516(1): 37-43. |
| 14 | YANG W H, DING C C, SUN T, et al. The hippo pathway effector TAZ regulates ferroptosis in renal cell carcinoma[J]. Cell Rep, 2019, 28(10): 2501-2508.e4. |
| 15 | XIE Y, ZHU S, SONG X, et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity[J]. Cell Rep, 2017, 20(7): 1692-1704. |
| 16 | MURI J, KOPF M. Redox regulation of immunometabolism[J]. Nat Rev Immunol, 2021, 21(6): 363-381. |
| 17 | ZOU Y L, LI H X, GRAHAM E T, et al. Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis[J]. Nat Chem Biol, 2020, 16(3): 302-309. |
| 18 | SUZUKI T, MOTOHASHI H, YAMAMOTO M. Toward clinical application of the Keap1-Nrf2 pathway[J]. Trends Pharmacol Sci, 2013, 34(6): 340-346. |
| 19 | CONRAD M, PRATT D A. The chemical basis of ferroptosis[J]. Nat Chem Biol, 2019, 15(12): 1137-1147. |
| 20 | KAGAN V E, MAO G W, QU F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis[J]. Nat Chem Biol, 2017, 13(1): 81-90. |
| 21 | DIXON S J, WINTER G E, MUSAVI L S, et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death[J]. ACS Chem Biol, 2015, 10(7): 1604-1609. |
| 22 | DOLL S, PRONETH B, TYURINA Y Y, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition[J]. Nat Chem Biol, 2017, 13(1): 91-98. |
| 23 | LAGROST L, MASSON D. The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease[J]. Curr Opin Lipidol, 2022, 33(3): 193-198. |
| 24 | BERSUKER K, HENDRICKS J M, LI Z P, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis[J]. Nature, 2019, 575(7784): 688-692. |
| 25 | DOLL S, FREITAS F P, SHAH R, et al. FSP1 is a glutathione-independent ferroptosis suppressor[J]. Nature, 2019, 575(7784): 693-698. |
| 26 | KUHN H, BANTHIYA S, VAN LEYEN K. Mammalian lipoxygenases and their biological relevance[J]. Biochim Biophys Acta, 2015, 1851(4): 308-330. |
| 27 | KRAFT V A N, BEZJIAN C T, PFEIFFER S, et al. GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling[J]. ACS Cent Sci, 2020, 6(1): 41-53. |
| 28 | GAO M, MONIAN P, QUADRI N, et al. Glutaminolysis and transferrin regulate ferroptosis[J]. Mol Cell, 2015, 59(2): 298-308. |
| 29 | LEE H, ZANDKARIMI F, ZHANG Y L, et al. Energy-stress-mediated AMPK activation inhibits ferroptosis[J]. Nat Cell Biol, 2020, 22(2): 225-234. |
| 30 | SHIN D, LEE J, YOU J H, et al. Dihydrolipoamide dehydrogenase regulates cystine deprivation-induced ferroptosis in head and neck cancer[J]. Redox Biol, 2020, 30: 101418. |
| 31 | URSINI F, MAIORINO M, VALENTE M, et al. Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides[J]. Biochim Biophys Acta, 1982, 710(2): 197-211. |
| 32 | URSINI F, MAIORINO M, GREGOLIN C. Phospholipid hydroperoxide glutathione peroxidase[J]. Int J Tissue React, 1986, 8(2): 99-103. |
| 33 | ALIM I, CAULFIELD JT, CHEN Y, et al. Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke[J]. Cell, 2019, 177(5): 1262-1279.e25. |
| 34 | VENKATESH D, O'BRIEN N A, ZANDKARIMI F, et al. MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling[J]. Genes Dev, 2020, 34(7/8): 526-543. |
| 35 | SOULA M, WEBER R A, ZILKA O, et al. Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers[J]. Nat Chem Biol, 2020, 16(12): 1351-1360. |
| 36 | MAO C, LIU X G, ZHANG Y L, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer[J]. Nature, 2021, 593(7860): 586-590. |
| 37 | CHEN X, KANG R, KROEMER G, et al. Broadening horizons: the role of ferroptosis in cancer[J]. Nat Rev Clin Oncol, 2021, 18(5): 280-296. |
| 38 | JIANG L, KON N, LI T Y, et al. Ferroptosis as a p53-mediated activity during tumour suppression[J]. Nature, 2015, 520(7545): 57-62. |
| 39 | CHEN D, FAN Z, RAUH M, et al. ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner[J]. Oncogene, 2017, 36(40): 5593-5608. |
| 40 | WU J, MINIKES A M, GAO M H, et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling[J]. Nature, 2019, 572(7769): 402-406. |
| 41 | GAO R Z, KALATHUR R K R, COTO-LLERENA M, et al. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis[J]. EMBO Mol Med, 2021, 13(12): e14351. |
| 42 | SINGHAL R, MITTA S R, DAS N K, et al. HIF-2α activation potentiates oxidative cell death in colorectal cancers by increasing cellular iron[J]. J Clin Invest, 2021, 131(12): e143691. |
| 43 | HANGAUER M J, VISWANATHAN V S, RYAN M J, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition[J]. Nature, 2017, 551(7679): 247-250. |
| 44 | YANG W S, SRIRAMARATNAM R, WELSCH M E, et al. Regulation of ferroptotic cancer cell death by GPX4[J]. Cell, 2014, 156(1/2): 317-331. |
| 45 | GASCHLER M M, ANDIA A A, LIU H R, et al. FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation[J]. Nat Chem Biol, 2018, 14(5): 507-515. |
| 46 | LOUANDRE C, EZZOUKHRY Z, GODIN C, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib[J]. Int J Cancer, 2013, 133(7): 1732-1742. |
| 47 | HADIAN K, STOCKWELL B R. SnapShot: ferroptosis[J]. Cell, 2020, 181(5): 1188-1188.e1. |
| 48 | VISWANATHAN V S, RYAN M J, DHRUV H D, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway[J]. Nature, 2017, 547(7664): 453-457. |
| 49 | ELING N, REUTER L, HAZIN J, et al. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells[J]. Oncoscience, 2015, 2(5): 517-532. |
| 50 | ANGELI J P F, SCHNEIDER M, PRONETH B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice[J]. Nat Cell Biol, 2014, 16(12): 1180-1191. |
| 51 | TANG B F, ZHU J Y, LI J, et al. The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma[J]. Cell Commun Signal, 2020, 18(1): 174. |
| 52 | KONG R, WANG N, HAN W, et al. IFNγ-mediated repression of system xc- drives vulnerability to induced ferroptosis in hepatocellular carcinoma cells[J]. J Leukoc Biol, 2021, 110(2): 301-314. |
| 53 | WU S, YANG J, SUN G L, et al. Macrophage extracellular traps aggravate iron overload-related liver ischaemia/reperfusion injury[J]. Br J Pharmacol, 2021, 178(18): 3783-3796. |
| 54 | YAMADA N, KARASAWA T, WAKIYA T, et al. Iron overload as a risk factor for hepatic ischemia-reperfusion injury in liver transplantation: potential role of ferroptosis[J]. Am J Transplant, 2020, 20(6): 1606-1618. |
| 55 | LI Y, FENG D C, WANG Z Y, et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion[J]. Cell Death Differ, 2019, 26(11): 2284-2299. |
| 56 | FANG X X, WANG H, HAN D, et al. Ferroptosis as a target for protection against cardiomyopathy[J]. Proc Natl Acad Sci USA, 2019, 116(7): 2672-2680. |
| 57 | ZHOU Z, YE T J, BONAVITA G, et al. Adipose-specific lipin-1 overexpression renders hepatic ferroptosis and exacerbates alcoholic steatohepatitis in mice[J]. Hepatol Commun, 2019, 3(5): 656-669. |
| 58 | LI Z Y, AGELLON L B, ALLEN T M, et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis[J]. Cell Metab, 2006, 3(5): 321-331. |
| 59 | NELSON J E, WILSON L, BRUNT E M, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease[J]. Hepatology, 2011, 53(2): 448-457. |
| 60 | CHEN X, KANG R, KROEMER G, et al. Ferroptosis in infection, inflammation, and immunity[J]. J Exp Med, 2021, 218(6): e20210518. |
| 61 | YU Y, JIANG L, WANG H, et al. Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis[J]. Blood, 2020, 136(6): 726-739. |
| 62 | ZHANG Z L, YAO Z, WANG L, et al. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells[J]. Autophagy, 2018, 14(12): 2083-2103. |
| 63 | WANG H, AN P, XIE E J, et al. Characterization of ferroptosis in murine models of hemochromatosis[J]. Hepatology, 2017, 66(2): 449-465. |
| 64 | WU A M, FENG B, YU J, et al. Fibroblast growth factor 21 attenuates iron overload-induced liver injury and fibrosis by inhibiting ferroptosis[J]. Redox Biol, 2021, 46: 102131. |
| 65 | ZAMPIERI S, MELLON S H, BUTTERS T D, et al. Oxidative stress in NPC1 deficient cells: protective effect of allopregnanolone[J]. J Cell Mol Med, 2009, 13(9b): 3786-3796. |
| 66 | VÁZQUEZ M C, BALBOA E, ALVAREZ A R, et al. Oxidative stress: a pathogenic mechanism for Niemann-Pick type C disease[J]. Oxid Med Cell Longev, 2012, 2012: 205713. |
| 67 | FU R, YANJANIN NM, BIANCONI S, et al. Oxidative stress in Niemann-Pick disease, type C[J]. Mol Genet Metab, 2010, 101(2/3): 214-218. |
| [1] | 王静怡, 邓佳丽, 朱仪, 丁心怡, 郭嘉婧, 王中领. 新型pH响应性锰基纳米探针用于乳腺癌铁死亡及磁共振成像实验研究[J]. 上海交通大学学报(医学版), 2025, 45(9): 1183-1193. |
| [2] | 万宏劲, 胡逸斌, 王昕, 张凯, 秦安, 马培翔, 马辉, 赵杰. 甲基莲心碱通过KEAP1/NRF2/GPX4和NF-κB信号通路减轻椎间盘退行性变[J]. 上海交通大学学报(医学版), 2025, 45(3): 261-270. |
| [3] | 李文丽, 钟方元, 赵怡超, 金力行, 雷杰, 石瑶, 卜军, 葛恒. 血红蛋白诱导心肌细胞铁死亡及Basigin的调控机制研究[J]. 上海交通大学学报(医学版), 2025, 45(12): 1559-1567. |
| [4] | 李广慧, 冯晓玲. 复发性流产中胎盘细胞铁死亡的研究进展[J]. 上海交通大学学报(医学版), 2025, 45(10): 1383-1389. |
| [5] | 谢滨, 白蒙, 吴妍, 沃璐璐, 黄莺, 张晶. SUMO特异性蛋白酶1在铁死亡中的潜在作用[J]. 上海交通大学学报(医学版), 2025, 45(1): 11-19. |
| [6] | 牛媛媛, 汪龙德, 胥文娟, 李正菊, 张瑞婷, 吴毓谦. 巨噬细胞M1/M2型极化在不同肝病中的作用研究进展[J]. 上海交通大学学报(医学版), 2024, 44(4): 509-517. |
| [7] | 杜玉婷, 张婧, 黄莺, 张晶. 铁死亡对肌肉损伤后再生能力的影响[J]. 上海交通大学学报(医学版), 2022, 42(3): 298-306. |
| [8] | 魏倩, 张颖婷, 林龙帅, 何恩俊, 何咏元, 苏滢泓, 段澄澄, 王斯源, 赵庆华, 赵倩, 贺明. 结合珠蛋白通过抑制ERK1/2减轻肝细胞铁死亡[J]. 上海交通大学学报(医学版), 2021, 41(8): 999-1008. |
| [9] | 贺 明,魏 倩,张颖婷. 铁死亡相关机制与其在肝脏相关疾病中作用的研究进展[J]. 上海交通大学学报(医学版), 2020, 40(11): 1519-1523. |
| [10] | 南 楠,詹 平. 锌对砷致雄性大鼠睾丸毒性损伤的拮抗作用[J]. 上海交通大学学报(医学版), 2013, 33(12): 1637-. |
| [11] | 孙 超, 范建高. 诱导多能干细胞在肝脏疾病中的研究进展[J]. , 2012, 32(5): 667-. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||